Brosseau warns that, unless the government amends the Act with respect to the minimum reimbursement of 68% imposed by the rules governing the RGAM, and unless private plans introduce appropriate control measures, which several Aon clients have successfully done in Québec, the benefits for private plans of reducing the cost of generic drugs to 25% will be negligible, compared to those enjoyed by the RAMQ.
She points out that Aon formed an association of private plan sponsors in 2005 for the purpose of speaking out against these inequities. “To date, the government has turned a deaf ear, and we must ask why the organizations that are responsible for defending the rights of employers and unions have not insisted on securing the reforms that have become necessary since the introduction of the RGAM in 1997,” she says.
“We hope that employers and unions will now mobilize and join this association with a view to bringing about the necessary changes and obtaining the right to use the same tools as the RAMQ in order to control the cost of private drug plans in Québec.
